Graft clonogenicity and intensity of pre-treatment: Factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission

Bone Marrow Transplantation

Volumn 36, Issue 12, 2005, Pages 1083-1088

  Strodtbeck, D ^a   Bornhauser M ^a   Hanel M ^b   Lerche, L ^a   Schaich, M ^a   Illmer, T ^a   Thiede, C ^a   Geissler, G ^b   Herbst, R ^b   Ehninger, G ^a   Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

Author keywords

AML; Autologous transplantation; FLT3; Megakaryocytic progenitors; Reconstitution

Indexed keywords

AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLONOGENESIS; COLONY FORMING UNIT; CONVALESCENCE; CORRELATION ANALYSIS; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; KARYOTYPE; LONG TERM CARE; MALE; MEGAKARYOCYTE; NEUTROPHIL; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEM CELL MOBILIZATION; THROMBOCYTE; THROMBOCYTE COUNT;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; KARYOTYPING; LEUKAPHERESIS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MEGAKARYOCYTES; MIDDLE AGED; MUTATION; REMISSION INDUCTION; STEM CELLS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 30544437627     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705176     Document Type: Article

References (20)

1. Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: A meta-analysis. J Natl Cancer Inst 2004; 96: 38-45.
2. Vey N, Bouabdallah R, Stoppa A et al. Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: A 6-year follow-up study of 101 patients from a single institution. Bone Marrow Transplant 2004; 33: 177-182.
3. Kottaridis PD, Gale RE, Linch DC. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leukemia Lymphoma 2003; 44: 905-913.
4. Feller N, Schuurhuis GJ, van der Pol MA et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003; 17: 68-75.
5. de la Rubia J, Sanz GF, Martin G et al. Autologous blood stem cell transplantation for acute myeloblastic leukemia in first complete remission. Intensification therapy before transplantation does not prolong disease-free survival. Haematologica 1999; 84: 125-132.
6. Carral A, de la Rubia J, Martin G et al. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplant 2002; 29: 825-832.
7. Reiffers J, Stoppa AM, Attal M et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with te myeloid leukemia in first remission: The BGMT 87 study. Leukemia 1996; 10: 1874-1882.
8. Gorin NC, Labopin M, Laporte JP et al. Importance of marrow dose on posttransplant outcome in acute leukemia: Models derived from patients autografted with mafosfamide-purged marrow at a single institution. Exp Hematol 1999; 27: 1822-1830.
9. Gorin NC, Labopin M, Pichard P et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: Importance of the source of stem cells. Br J Haematol 2000; 110: 887-893.
10. Reichle A, Rothe G, Krause S et al. Transplant characteristics: Minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Leukemia 1999; 13: 1227-1234.
11. Lowenthal RM, Faberes C, Marit G et al. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: A retrospective analysis of a 10-year single institution experience. Bone Marrow Transplant 1998; 22: 763-770.
12. Schaich M, Illmer T, Seitz G et al. The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. Haematologica 2001; 86: 470-477.
13. Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
14. Platzbecker U, Prange-Krex G, Bornhauser M et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001; 41: 184-189.
15. Feller N, Schuurhuis GJ, van der Pol MA et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003; 17: 68-75.
16. Gorin NC. Autologous stem cell transplantation for adult acute leukemia. Curr Opin Oncol 2002; 14: 152-159.
17. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003; 17: 1738-1752.
18. Lowenthal RM, Faberes C, Marit G et al. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: A retrospective analysis of a 10-year single institution experience. Bone Marrow Transplant 1998; 22: 763-770.
19. Reichle A, Rothe G, Krause S et al. Transplant characteristics: Minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Leukemia 1999; 13: 1227-1234.
20. Jourdan E, Rigal-Huguet F, Marit G et al. One vs two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. Br J Haematol 2005; 129: 403-410.